Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H36N4O5S.CH4O3S |
Molecular Weight | 624.769 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC(C)(N)C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CN(C4=C3C=CC=C4)S(C)(=O)=O)CC2
InChI
InChIKey=DUGMCDWNXXFHDE-VZYDHVRKSA-N
InChI=1S/C27H36N4O5S.CH4O3S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27;1-5(2,3)4/h4-12,22H,13-19,28H2,1-3H3,(H,29,33);1H3,(H,2,3,4)/t22-;/m1./s1
DescriptionSources: http://adisinsight.springer.com/drugs/800007434Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18923064 | https://www.ncbi.nlm.nih.gov/pubmed/7624358 | https://www.ncbi.nlm.nih.gov/pubmed/9329386
Sources: http://adisinsight.springer.com/drugs/800007434
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18923064 | https://www.ncbi.nlm.nih.gov/pubmed/7624358 | https://www.ncbi.nlm.nih.gov/pubmed/9329386
Ibutamoren (L-163,191 MK-0677) is a spiropiperidine agonist of the ghrelin receptor and a growth hormone secretagogue. Ibutamoren mimics the actions of growth hormone releasing peptide-6 to increase serum levels of serum insulin-like growth factor-I (IGF-I). Orally active Ibutamoren was being developed by Merck & Co. for a variety of indications, including fibromyalgia, muscle wasting/weakness in patients with chronic kidney disease, Alzheimer's disease and fractures.However, there has been no recent development reported or development has been discontinued for these indications.
Originator
Sources: http://adisinsight.springer.com/drugs/800007434
Curator's Comment: # Merck & Co
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P01241 Gene ID: 2688.0 Gene Symbol: GH1 Target Organism: Homo sapiens (Human) |
1.3 nM [EC50] | ||
0.3 nM [EC50] | |||
Target ID: CHEMBL3217394 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9329386 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18981485
25 mg once daily: over 12 months, the ghrelin mimetic Ibutamoren (L-163,191 MK-0677) enhanced pulsatile growth hormone secretion, significantly increased fat-free mass, and was generally well tolerated. Long-term functional and, ultimately, pharmacoeconomic, studies in elderly persons are indicated.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12486113
1 uM MK-0677 inhibits cell death and activate ERK1/2 and Akt in H9c2 cardiomyocytes and PAE.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
579617
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
||
|
DSLD |
4043 (Number of products:1)
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
||
|
NCI_THESAURUS |
C1910
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/17/1882
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C094817
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
1805437
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
159752-10-0
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL13817
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
R90JB6QJ2B
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
6450830
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
C97489
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
100000175137
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
II-74
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
DTXSID50936168
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
R90JB6QJ2B
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD